Job losses have been confirmed at Irvine's GSK plant with around 60 worker's positions at risk.

GSK confirmed the redundancies today [August 20] after staff at the plant had been told the sad news.

The chemical and pharmaceutical giant added this was due to the the plant no longer planning to process the chemical 6-APA on-site.

A GSK spokesperson said: "Following a detailed review of our supply chain, we have announced a proposal to change some of our manufacturing operations at GSK’s Irvine site.

"While we will continue to manufacture Clavulanic acid, we will no longer manufacture 6-APA on-site and will instead purchase this from validated external suppliers.

"This decision will result in a reduction in the number of roles on site and we have opened consultation with employees and their representatives. As always, we will treat employees fairly, with respect and integrity. 

"We remain committed to the manufacture of Augmentin and to our Irvine site, which has played a key role in in the supply of Active Pharmaceutical Ingredients for GSK’s antibiotics for almost 50 years."